J 2023

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

PULANIC, Drazen, Angelika BATOROVA, Imre BODO, Libor ČERVINEK, Ioana IONITA et. al.

Basic information

Original name

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

Authors

PULANIC, Drazen (guarantor), Angelika BATOROVA, Imre BODO, Libor ČERVINEK (203 Czech Republic, belonging to the institution), Ioana IONITA, Toshko LISSITCHKOV, Anahit MELIKYAN and Maria PODOLAK-DAWIDZIAK

Edition

Annals of hematology, New York, Springer Verlag, 2023, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.500 in 2022

RIV identification code

RIV/00216224:14110/23:00130690

Organization unit

Faculty of Medicine

DOI

UT WoS

000939356900001

Keywords in English

Immune thrombocytopenia; Thrombopoietin receptor agonists; Systematic review; Consensus; Eltrombopag; Romiplostim; Avatrombopag

Tags

Tags

International impact, Reviewed
Změněno: 2/5/2023 09:35, Mgr. Tereza Miškechová

Abstract

V originále

There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate (R)), eltrombopag (Revolade (R)), and avatrombopag (Doptelet (R)). However, comparative clinical data between these TPO-RAs are limited. Therefore, the purpose of this study was to perform a literature review and seek expert opinion on the relevance and strength of the evidence concerning the use of TPO-RAs in adults with ITP. A systematic search was conducted in PubMed and Embase within the last 10 years and until June 20, 2022. A total of 478 unique articles were retrieved and reviewed for relevance. The expert consensus panel comprised ITP senior hematologists from eight countries across Central Europe. The modified Delphi method, consisting of two survey rounds, a teleconference and email correspondence, was used to reach consensus. Forty articles met the relevancy criteria and are included as supporting evidence, including five meta-analyses analyzing all three European-licensed TPO-RAs and comprising a total of 31 unique randomized controlled trials (RCTs). Consensus was reached on seven statements for the second-line use of TPO-RAs in the management of adult ITP patients. In addition, the expert panel discussed TPO-RA treatment in chronic ITP patients with mild/moderate COVID-19 and ITP patients in the first-line setting but failed to reach consensus. This work will facilitate informed decision-making for healthcare providers treating adult ITP patients with TPO-RAs. However, further studies are needed on the use of TPO-RAs in the first-line setting and specific patient populations.